General information:
Substance group: direct oral anticoagulant (DOAK) / selective factor xa inhibitor ATC: B01AF02
Trade name: Eliquis®
dosages available: film tablets 2.5 / 5 mg
Reference ranges:
For the prophylaxis of strokes and systemic embolisms in non-valvular atrial fibrillation:
2x5mg
Cmax (1-3h after ingestion): 171 ng/mL (91-321 ng/mL)
Trough level (before the next intake): 103 ng/mL (41-230 ng/mL)
2 x 2.5mg
Cmax (1-3h after ingestion): 123 ng/mL (69-221 ng/mL)
Trough level (before the next intake): 79 ng/mL (34-162 ng/mL)
To treat deep vein thrombosis and pulmonary embolisms and for the prevention of relapsing deeper vein thrombosis and pulmonary embolism:
2x10mg
Cmax (1-3h after ingestion): 251 ng/mL (111-572 ng/mL)
Trough level (before the next intake): 120 ng/mL (41-335 ng/mL)
2x5mg
Cmax (1-3h after ingestion): 132 ng/mL (59-302 ng/mL)
Trough level (before the next intake): 63 ng/mL (22-177 ng/mL)
2 x 2.5mg
Cmax (1-3h after ingestion): 67 ng/mL (30-153 ng/mL)
Valley mirror (before next intake): 32 ng/mL (11-90 ng/mL)
For the prophylaxis of venous thromboembolism after elective hip or knee replacement surgery:
2 x 2.5mg
Cmax (1-3h after intake): 77 ng/mL (41-146 ng/mL)
Tale mirror (before the next intake): 51 ng/mL (23-109 ng/mL)
Toxic dose: not established yet
Sampling:
Material: Citrate Plasma (Monovette Green) Minimum volume for analysis: 500µl
Recommendation: trough level (directly before the next intake)
Request (internal): … Requirement (external): after consultation (+49 221 478 5066)
Analytics:
Test principle: liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS)
Protein precipitation with acetonitrile, chromatographic separation, mass spectrometry
Analysis according to mass charge ratio
Analysis system: triple stage Quadrupol mass spectrometer (LC-MS/MS)
Findings communication: on the day of submission, via LIMS
DrugBank: https://go.drugbank.com/drugs/DB0660